It was hypothesized that R, Z)-3-(6-(dimethylamino)-6-oxohex-1-enyl)-N-(1-hydroxypropan-2-yl) benzamide (VSN16R), a novel orally active, neuronally selective (no activity against the smooth muscle forms α1β1) BK channel opener [11,26], may therefore also exhibit neuroprotective potential in MS, in the absence of immunosuppressive activity. Here, KCNMA1 is linked to myeloid sarcoma.